France’s accès précoce (early access) scheme is one of the most attractive routes to market in Europe. Manufacturers can make an innovative medicine available to
Written by Johann Sanseau, Associate Consultant: [email protected] Haute Autorité de Santé (HAS) recently granted post-Marketing Authorisation (MA) early access (accès précoce) to Ojemda™ (tovorafenib) for
Written by Thea Collier-Lawlor, Senior Analyst: [email protected] Pricing in Brazil is about to undergo the most significant reform in the last 20 years, with the
Written by Miriam Belmonte, Consultant [email protected] Cost effectiveness threshold change The UK government has confirmed a major policy change: from April 2026, NICE’s cost-effectiveness threshold will rise for the
Written by Pina Haberl, Senior Director & Chief People Officer Disclaimer: (Last updated: May 22, 2025 | Subject to final G-BA plenary resolution in July
Written by Johann Sanseau, Associate Consultant In 2024, the Haute Autorité de Santé (HAS) celebrated 20 years of innovation and rigor, with their 2024 activity
Written by Thea Collier- Lawlor, Analyst & Josh McLuckie, Analsyt The well-known challenges faced by developers of advanced therapies for rare diseases have been under
Patient involvement in health technology assessment (HTA) has come a long way. Once seen as an optional add-on, it is now a key element of
How the EU JCA is impacting France’s HTA process—key updates on reimbursement, early access, and scientific advice
